Table 6.

Distribution of Deaths - NSABP STAR Trial (P-2)

Cause of deathDeaths, n
TamoxifenRaloxifene
Cancer10186
    Bladder13
    Bone, articular cartilage and connective tissue11
    Brain64
    Breast114
    Colon43
    Endocrine gland01
    Gallbladder21
    Kidney11
    Liver71
    Lung2528
    Lymphatic/hematopoietic1211
    Oral21
    Ovary87
    Pancreas75
    Peritoneum20
    Skin20
    Spleen01
    Stomach21
    Thyroid10
    Uterus22
    Other, uncertain, and unspecified sites511
Circulatory/vascular disease4242
    Aortic12
    Atherosclerosis01
    Cerebrovascular disease, unspecified10
    Hypertensive disease14
    Ischemic heart disease138
    Other heart disease914
    Peripheral vascular disease, unspecified01
    Polyarteritis nodosa01
    Pulmonary embolism32
    Primary pulmonary hypertension10
    Stroke139
Other9374
    Accident, auto34
    Accident, fire10
    Alcohol dependence syndrome11
    Asphyxiation and strangulation10
    Complications of surgery01
    Dementia01
    Diabetes13
    Disorders of metabolism10
    Emphysema10
    Injury, intracranial22
    Injury, other10
    Interferon toxicity01
    Intestinal infectious disease01
    Other conditions of the blood02
    Other conditions of the brain/neurological system73
    Other diseases of the digestive system76
    Other Diseases of the urinary system21
    Other respiratory disease137
    Pneumonia24
    Poisoning20
    Septicemia43
    Skin infections01
    Symptoms, signs, and ill-defined conditions23
    Unknown4230
Total deaths (rate per 1,000)236 (3.81)202 (3.22)
    Risk ratio (95% CI)0.70–1.02)

Abbreviations: CI, confidence interval; NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene.